StockNews.AI
NAMS
StockNews.AI
111 days

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

1. NewAmsterdam Pharma presents obicetrapib data at EAS Congress. 2. Obicetrapib shows potential for LDL-C reduction in cardiovascular patients. 3. Phase 3 trial results indicate efficacy alongside ezetimibe. 4. Presentations include insights on atherosclerosis and vascular inflammation. 5. Company targets unmet needs in LDL-lowering therapies.

6m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical data can enhance investor confidence and drive demand, similar to past successes of biotech firms like Amgen following trial results.

How important is it?

The presentation of new data can significantly sway market opinions on NAMS’s viability in the biotech sector.

Why Short Term?

Upcoming presentations can lead to immediate investor interest and stock price movements, reminiscent of events like Gilead's presentation of breakthrough therapies.

Related Companies

AMGNGILDREGNVRTX
Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers April 30, 2025 08:00 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, the Netherlands and MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 93rd Congress, taking place on May 4-7, 2025 in Glasgow, UK. Late-breaker oral presentation details are as follows: Title: Fixed-Dose Combination of Obicetrapib and Ezetimibe for LDL-C Reduction: A Phase 3 Randomized TrialSession Name: Late Breaker Session: ClinicalOral Presentation Date and Time: Wednesday, May 5, 2025, 12:00-12:15 PM BST (7:00-7:15 AM ET)Location: William Harvey Hall Title: Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskSession Name: Late Breaker Session: ClinicalOral Presentation Date and Time: Wednesday, May 5, 2025, 12:15-12:30 PM BST (7:15-7:30 AM ET)Location: Will Harvey Hall Additional session details are as follows: Title: Obicetrapib Reduces Atherosclerosis and Vascular Inflammation, Mainly by Reducing Non-HDL Cholesterol, Improves Lesion Stability and Adds to the Beneficial Effects of EzetimibeSession Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and OutcomesPresentation Date and Time: Monday, May 5, 2025, 1:58-2:05 PM BST (8:58-9:05 AM ET)Location: Station 7 Title: Obicetrapib Alone and in Combination with Ezetimibe Increases Reverse Cholesterol Transport and Does Not Affect VLDL ProductionSession Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and OutcomesPresentation Date and Time: Monday, May 5, 2025, 2:05-2:12 PM BST (9:05-9:12 AM ET)Location: Station 7 Title: Low-Dose Obicetrapib Significantly Increases Concentrations of Lipophilic Antioxidants, ApoE, and S1P in HDL SubfractionsSession Name: SaaG Session: Lipid Lowering Therapies and Advances in Vascular TherapeuticsPresentation Date and Time: Monday, May 5, 2025, 2:19-2:26 PM BST (9:19-9:26 AM ET)Location: Station 4 Title: Obicetrapib Significantly Increases Plasma and High-Density Lipoprotein (HDL) Levels of Lipophilic AntioxidantsSession Name: SaaG Session: Lipoprotein Dynamics: HDL to RemnantsPresentation Date and Time: Monday, May 5, 2025, 3:17-3:24 PM BST (10:17-10:24 AM ET)Location: Station 3 Title: Efficacy and Safety of Combination Obicetrapib with Moderate-Dose StatinsSession Name: Poster Networking SessionsPresentation Date and Time: Monday, May 5 & Tuesday, May 6, 2025, 5:20 - 6:50 PM BST (12:17-1:24 PM ET)Location: Poster Board #246, Exhibition Hall Title: Safety and Efficacy of Cholesteryl Ester Transfer Protein Inhibition: From Genetics to Outcome TrialsSession Name: Workshop: New risk factors for atherosclerotic diseasePresentation Date and Time: Wednesday, May 7, 2025, 12:20 -12:30 PM BST (7:17-8:24 AM ET)Location: James Black Hall About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew PhilippeP: 1-917-882-7512matthew.philippe@newamsterdampharma.com Media Contact Spectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@spectrumscience.com Investor Contact Precision AQ on behalf of NewAmsterdamAustin MurtaghP: 1-212-698-8696austin.murtagh@precisionaq.com

Related News